Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2020-03-09 Proxy Solicitation & In…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Hyundai Bioscience. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, appointment of auditors, and director remuneration limits. It also includes detailed proxy information, such as electronic voting procedures and background information on director candidates. This document is designed to provide shareholders with the necessary information to vote at the meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2020-03-09 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Reference Document' (참고서류) for a General Meeting of Shareholders, specifically for the 20th Annual General Meeting of Hyundai Bioscience. It contains detailed agenda items such as the approval of financial statements, appointment of an auditor, and approval of director/auditor remuneration limits. This type of document is provided to shareholders to solicit proxies and provide information for voting at the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2020-03-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 98% confidence The document is a regulatory filing from Hyundai Bioscience regarding a significant change (30% or more) in sales or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial changes before the final annual report is audited and published. It provides key financial highlights and reasons for the variance, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial results.
2020-02-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure by insiders (executives or major shareholders) regarding changes in their shareholdings. In the context of the provided categories, this falls under 'Major Shareholding Notification' (MRQ) as it details the change in ownership percentage and specific securities held by a major shareholder (CnPharm Co., Ltd.) in the issuing company (Hyundai Bioscience).
2020-01-13 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings Classification · 95% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. It details changes in share ownership by a major shareholder (CnPharm Co., Ltd.) and special related parties in Hyundai Bioscience. This type of filing is a standard regulatory disclosure regarding significant ownership thresholds and does not fit into specific categories like earnings releases or annual reports. Therefore, it is classified as a Regulatory Filing (RNS).
2020-01-13 Korean
전환청구권행사(제7회차)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Hyundai Bioscience regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (CB). It details the number of shares issued upon conversion, the conversion price, and the remaining balance of the convertible bonds. This type of filing relates to changes in capital structure and share issuance resulting from debt conversion, which falls under the 'Share Issue/Capital Change' category.
2020-01-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.